novavax covid fda approvalviva chicken plantains

The company released data in late December that found two doses of its vaccine triggered a strong immune response against the original omicron variant, though three doses appeared to be better. Novavax's shot, which is already available in over 40 countries, is a more traditional type of vaccine employing technology that has been used for decades to combat diseases like influenza. "Anything we can do to get people more comfortable to be able to accept these potentially life-saving medical products is something that we feel we are compelled to do," he added. With the Covid emergency I suspended my practice of . Novavax Inc will submit a request to the U.S. Food and Drug Administration to authorize its COVID-19 vaccine next month, further delaying the submission it had expected by the end of this year. The companys trials were conducted when the Alpha variant of the coronavirus was the predominant strain. U kunt uw keuzes te allen tijde wijzigen door te klikken op de links 'Privacydashboard' op onze sites en in onze apps. The FDA also expects Novavax Inc. to continue their clinical trials to obtain additional safety and effectiveness data and pursue approval (licensure). Novavax has said it will continuously monitor for all adverse events potentially related to the vaccine, including myocarditis. Infections are rare and can be severe or fatal, but so far scientists don't see genetic changes that pose an increased threat to people. Mountain lions, a bobcat, red foxes, black bears, and skunks represent the latest avian flu cases in mammals. The FDA has evaluated the pharmacovigilance plan submitted by the company to monitor the safety of Novavax COVID-19 Vaccine, Adjuvanted as it will be used under EUA to ensure that any safety concerns are identified and evaluated in a timely manner. Novavax has submitted an application to the Food and Drug Administration for Emergency Use Authorization of its COVID-19 vaccine as a booster in adults that can be used on top of its primary vaccine series or to mix and match with a different primary series, the company announced. The U.S. has secured 3.2 million doses of the vaccine, ready to be shipped to states once it receives the green light, the Biden administration announced Monday. Digestive symptoms, like stomach pain, might be among the earliest symptoms of COVID-19 that you experience. Effective subunit vaccines have also been developed for pertussis (whooping cough), hepatitis B, and other diseases, giving this type of vaccine a strong track record. The US Food and Drug Administration on Wednesday authorized Novavax's Covid-19 vaccine for emergency use in adults. Novavax is waiting for approval from the Food and Drug Administration to start rolling out its COVID-19 vaccine. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. This article. In addition, the FDA and the Centers for Disease Control and Prevention have several systems in place to continually monitor COVID-19 vaccine safety and allow for the timely detection and investigation of potential safety concerns. Additional disclosure: The information contained herein is for informational purposes only. Aircraft wastewater surveillance could be used with traveler-based surveillance to provide an early warning system for COVID-19 and other pathogens. This was an application for their protein-based Covid-19 vaccine Nuvaxovid (NVX-CoV2373) to be used as a booster, meaning a follow-up vaccine dose after someone has already received the primary series of Covid-19 shots. However, this study was done when the Alpha and Delta variants were circulating. The most recent research on the Omicron variant suggests it lives longer on surfaces than previous coronavirus variants. "We do have a problem with vaccine uptake that is very serious in the United States," FDA official Peter Marks told the panel. Biotech company Novavax has revealed its COVID-19 vaccine can generate effective . So, you may be asking, How effective might Nuvaxovid be as a heterologous booster? Well, a research letter recently published in the Journal of Infection described how Nuvaxovid boosters in nine individuals who had previously received two doses and 41 individuals who had previously received three doses of the Pfizer-BioNTech, the Moderna, or the Astra-Zeneca ones. (The mRNA vaccines delivered efficacy rates of 95 and 94 percent against the original coronavirus strain in Phase 3 trials, as compared with 96 percent for Novavax in its first trial, and now 90 . The FDA authorized the vaccine on Dec. 11 -- barely over three weeks later. Who the vaccine is indicated for; Effectiveness; Dosage; Vaccine ingredients; Possible side effects; Vaccine review, approval and monitoring Though COVID vaccines may utilize different delivery mechanisms, the end result is the same: cells in the body recognize that a spike protein (the spikes you see sticking out of the coronavirus in pictures) doesn't belong, and the immune system reacts by activating immune cells and producing antibodies to attack the real virus if you get exposed. Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, Adjuvanted for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. Latest vaccine will provide an additional option for the American public, pending FDA Emergency Use Authorization and CDC recommendation. Also, the additional costs place Novavax, Inc. in a more precarious financial position, though the company has a history of selling more shares and diluting shareholders. The latest subvariants, called BA.4 and BA.5, are considered the most contagious forms of the virus to date. While the company has provided the FDA with updated data, including the vaccines effectiveness against the Omicron variant, those data werent available for the external advisers at the time of their vote. (Photo by Patrick van Katwijk/Getty Images), Novavax announced that they had submitted a emergency use authorization (EUA) application, having received authorization for use in the European Union back in December 2021, the Japan Ministry of Health, Labour and Welfare (MHLW) had granted approval, a research letter recently published in the, only 4.4 million Americans have gotten the bivalent Covid19 mRNA boosters. Its more traditional technology and easy storage attracted big global investment but, as year two of the pandemic draws to a close, the company struggles with regulators, disappoints hopeful governments, and lags far behind its competitors. Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology. The U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense (DOD), today announced that it has secured 3.2 million doses of Novavax's COVID-19 vaccine. The FDA declined to comment, and the people with knowledge of the matter cautioned the plan could still change. The site is secure. Novavax says its COVID-19 vaccine was developed with more conventional methods than the vaccines already authorized for use in the US. Some people also think that since Novavax is based on a more traditional vaccine technology, those who are hesitant to receive an mRNA vaccine may be more likely to roll up their sleeves for this one. Wij, Yahoo, maken deel uit van de Yahoo-merkenfamilie. Apart from supportive care, there is only one drug approved, an antiviral (remdesivir), which can be used as a medical treatment for people with COVID-19, and an FDA emergency use-authorized nonvaccine antibody combination (casirivimab and imdevimab) to prevent infection. The company has a history of promising new vaccines while constantly diluting shareholders over and over with new share issuance. Five cases of myocarditis were identified in people who received the Novavax vaccine during the clinical trials. Among these participants, approximately 17,200 received the vaccine and approximately 8,300 received saline placebo. The vaccine uses synthetic coronavirus proteins to teach the bodys immune system to recognize bits of the virus. Als u niet wilt dat wij en onze partners cookies en persoonsgegevens voor deze aanvullende doeleinden gebruiken, klik dan op 'Alles weigeren'. The vaccine company Novavax, which manufactures COVID-19 vaccines, says it has "substantial doubts" about its own ability to stay in business long term. Approximately 21,000 vaccine recipients had at least two months of safety follow-up after their second dose. My investment thesis is Bearish on Novavax, Inc. stock following statements from the company about substantial doubt of a going concern due to heavy losses and questionable covid vaccine demand. Our Standards: The Thomson Reuters Trust Principles. Adjuvants are incorporated into some vaccines to enhance the immune response of the vaccinated individual. They made up about 70% of all new Covid cases in the U.S. for the week ending July 2, according to the CDC. Lees ons privacybeleid en cookiebeleid voor meer informatie over hoe we uw persoonsgegevens gebruiken. Because the Novavax vaccine is coming onto the scene late in the pandemic with the majority of vaccinated Americans receiving an mRNA vaccine its not clear what role this vaccine will play in the countrys COVID-19 response going forward. Please. In fact, Nuvaxovid has been available in other countries for even longer, having received authorization for use in the European Union back in December 2021 and in Japan in April 2022. The clearance, which happened Tuesday, followed years of questions about the strength of the data supporting Reata . The FDA authorization took "longer than we wanted," Novavax CEO Stanley Erck told NBC News in an interview, "but we're there and we have gotten the company's first approval with the FDA for a vaccine in the United States.". Despite the quick development of the COVID-19 vaccine, no corners were cut. Clinical trial results, published in The New England Journal of Medicine in December, found two doses of Novavaxs vaccine were about 90% effective. Novavax. He praised the company's perseverance with the vaccine and said its data are impressive. The company has also faced supply chain and clinical trial delays. Stocks in focus: Reata Pharmaceuticals stock soars after FDA-drug approval; Novavax falls after vaccine maker issues 'substantial doubts' over future operations Published: March 1, 2023 at 7: . In making this determination, the FDA can assure the public and medical community that a thorough analysis and evaluation of the available safety and effectiveness data and manufacturing information have been conducted. In other words, many could end up being rather bare naked should Covid-19 surge again soon. Novavax Chief Commercial Officer John Trizzino said the agency is still reviewing documents detailing its manufacturing processes submitted last week. The agency granted EUA to Moderna . Although it is too early to say for certain, initial estimates for the Pfizer vaccine and booster suggest up to 75 percent protection against. Last month, officials from the Centers for Disease Control and Prevention signed off on the use of Novavax's COVID-19 vaccine for Americans ages 18 years and older, making it the fourth COVID-19 vaccine to be made available to the American public. Two months later, there is still no sign of a decision from regulators. Full coverage of the coronavirus outbreak. Nothing in this article should be taken as a solicitation to purchase or sell securities. Novavaxs vaccine uses an older technology found in other widely used shots, offering people an alternative to the mRNA-based Pfizer and Moderna vaccines. Wij, Yahoo, maken deel uit van de Yahoo-merkenfamilie. part about this statement is that Novavax ended 2022 with a cash balance of $1.3 billion. On Dec. 31, Novavax announced that it submitted its final data package to the U.S. Food and Drug Administration and said it expects to file its application for emergency use approval by the end of . A vial of the Novavax Covid-19 vaccine arranged at a pharmacy in Schwenksville, Pennsylvania, Aug. 1, 2022. Structural changes in the brain may explain the persistent fatigue and neuropsychiatric complications tied to long COVID. Novavax experienced delays in early 2023 in manufacturing BA.5 clinical trial materials, which could potentially delay regulatory approval from the FDA for our vaccine candidate for the fall 2023 . Prior to covid, Novavax had done a 1-for-20 reverse split to reduce the share count. It is given in two doses, 3 weeks apart. The key investor takeaway is that Novavax, Inc. is a highly risky stock due to cash burn and constant share dilution. vaccines) in the U.S. since late 2020, most people due to get boosted now will have gotten the Covid-19 mRNA vaccines for their previous vaccinations. Full coverage and live updates on the Coronavirus. Food and Drug Administration. soared to amazing heights on exuberance around the approved covid vaccine, but now the gig is up. Looking for a portfolio of ideas like this one? The FDAs signoff isnt the last step: The decision will now to go the Centers for Disease Control and Prevention and its advisory committee to issue their own recommendation on how the shots should be used. In using an old standby technology, Nuvaxovid vaccines dont have to be kept as cold as the Covid-19 mRNA vaccines need to be kept, making Nuvaxovid vaccines a whole lot easier to transport and store. Thus, should Nuvaxovid be authorized as a booster, it would be probably be most useful as heterologous booster. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. Please disable your ad-blocker and refresh. Reuters, the news and media division of Thomson Reuters, is the worlds largest multimedia news provider, reaching billions of people worldwide every day. Novavax filed for emergency use for its COVID . Office of the Vice President for Research, University of Minnesota, Minneapolis, MN, 2023 Regents of the University of Minnesota. If approved for use in the U.S., it would make Novavax a latecomer to the COVID vaccine arsenal, though its vaccine is different from the mRNA vaccines supplied by Pfizer and Moderna. All rights reserved. As Novavax prepares to launch its initial shots in the U.S., the other vaccine manufacturers are working with administration officials to settle on reformulated vaccine boosters that better target the mutating virus and are expected to be distributed later this fall. Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile. The Covid-19 mRNA vaccines consist primarily of messenger RNA (mRNA) that serve as blueprints for your cells to manufacture spike proteins. 07/12/2022 12:55 PM EDT. The Barenaked Ladies may have sung, It's been one week since you looked at me. But its been eight weeks since Novavax announced that they had submitted a emergency use authorization (EUA) application to the U.S. Food and Drug Administration (FDA). . Europe has already been seeing upticks in Covid-19 cases and Covid-19-related hospitalizations. The most commonly reported side effects by vaccine recipients included pain/tenderness, redness and swelling at the injection site, fatigue, muscle pain, headache, joint pain, nausea/vomiting and fever. One potential safety concern raised during the FDA meeting is myocarditis inflammation of the heart muscle. This action gives people ages 18 years and older the option to receive a Novavax monovalent booster instead of an updated (bivalent) Pfizer-BioNTech or Moderna booster if they have completed primary series vaccination but have not previously received a . The Novavax vaccine is already approved for emergency use in other countries, and US officials hope that a vaccine made with a more traditional process might sway some who have been hesitant to be immunized against COVID-19. read more. By contrast, the Nuvaxovid vaccine includes the spike proteins themselves. Lees ons privacybeleid en cookiebeleid voor meer informatie over hoe we uw persoonsgegevens gebruiken. The biotech is competing with much larger biotechs in Pfizer (PFE), BioNTech SE (BNTX), and Moderna (MRNA), reducing the ability to effectively compete on covid vaccines when the company is seen as a distant third option, at best. Do Not Sell or Share My Personal Information. The unexpected data was delivered to a panel convened by the FDA to recommend booster plans for later this year. Novavax, a biotech company headquartered in Maryland, still needs to complete a final round of quality testing for its vaccine over the next several days. As a prime example, the company recently raised ~$250 million via a concurrent convertible debt offering and a public offering of 8.5 million shares at just $10 per shares. But the vaccine which relies on a protein-based technology used for decades may appeal to the sliver of the population allergic to components of the messenger RNA vaccines developed by Pfizer-BioNTech and Moderna, or who are skeptical of those shots newer technology. The company's Covid-19 shot, available in the U.S. under the Food and Drug Administration's emergency use authorization, has not yet earned a full regulatory approval from the agency. The trade name Nuvaxovid has not yet been approved by the U.S. Food and Drug Administration. About Nuvaxovid (NVX-CoV2373) Novavax's COVID-19 vaccine is a protein-based vaccine made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID-19. However, that demand has not materialized in Europe, where Novavax also said it could drive up vaccination among the hesitant. Patients have generally fewer adverse reactions like pain at the injection site, fever, headache, etc. The American public can trust that this vaccine, like all vaccines that are used in the United States, has undergone the FDAs rigorous and comprehensive scientific and regulatory review., FDA Evaluation of Available Effectiveness Data. And as of late September, only 4.4 million Americans have gotten the bivalent Covid19 mRNA boosters. Meanwhile, the FDA authorized vaccines from Moderna, Pfizer-BioNTech and Johnson & Johnson, and hundreds of millions of shots were rolled out for the Biden administrations vaccination campaign. Although half a million doses of Novavax's vaccine have now been distributed to states, following its authorization last month, just 9,700 doses of Novavax's COVID-19 vaccine have been administered across the country, according to federal data. But the possibility for fewer side effects and the use of reliable, trusted vaccine technology may work to convince those who remain unvaccinated to get their shot. The expected authorization comes after two years of setbacks for Novavax, once considered among the most promising Covid vaccine developers. By With nearly 22% of the nation yet to receive a single COVID-19 vaccine dose, federal vaccine advisers today recommended that the Novavax COVID-19 vaccine be approved under an emergency use authorization (EUA). The Novavax COVID-19 Vaccine, Adjuvanted has not been approved or licensed by the US Food and Drug Administration (FDA), but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19). The vaccine contains the SARS-CoV-2 spike protein and Matrix-M adjuvant. Erck said Novavax is confident its shot will provide strong protection against omicron and its family of subvariants. important to the nations vaccination campaign, published in The New England Journal of Medicine in December. Novavax is a COVID-19 vaccine that uses . If the Food and Drug Administration (FDA) accepts the group's recommendation and Centers for Disease Control and Prevention (CDC) advisers recommend it, Novavax would give the United States a fourth vaccine to battle the virus. Members of Out Fox The Street get exclusive access to our subscriber-only portfolios. Its been available in the U.S. as a two-dose primary series for adults (meaning for adults who havent received any Covid-19 vaccines yet) since mid-July after receiving an EUA on July 13 from the FDA. Out Fox the market with misunderstood, high reward opportunities. However, the clinical trials took place before the emergence of the extremely contagious omicron variant and its subvariants, which have been found to be more skilled at evading some of the immunity provided by other vaccines than previous strains. Can Probiotics Help Prevent or Treat COVID-19 Infection? Though, investors did have nearly a year to unload shares above $200 in another prime sign of how taking advantage of market opportunities is a must versus stubbornly holding a stock for the long term. The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs. Opinions expressed by Forbes Contributors are their own. In clinical trials, the Novavax vaccine was found to be 90% effective at preventing mild, moderate and severe COVID-19. It is also mandatory for vaccination providers to report all vaccine administration errors to VAERS for which they become aware and for Novavax Inc. to include a summary and analysis of all identified vaccine administration errors in monthly safety reports submitted to the FDA. Learn how it feels and how to manage it. Pfizer's and Moderna's vaccines have been associated with the heart inflammation condition, particularly in young men, though the complication remains rare. The measure passed with 21 yes votes and 1 abstention. If the Food and Drug Administration (FDA) accepts the group's recommendation and Centers for Disease Control and Prevention (CDC . CIDRAP - Center for Infectious Disease Research & Policy The company is preparing to file the FDA paperwork in coming weeks and could . Before shots can be administered, the FDA must authorize the vaccine and the Centers for Disease Control and Prevention (CDC) needs to green light its use. With nearly 22% of the nation yet to receive a single COVID-19 vaccine dose, federal vaccine advisers today recommended that the Novavax COVID-19 vaccine be approved under an emergency use authorization (EUA). Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks. "Based on the data presented to the FDA's VRBPAC and the CDC ACIP, we believe our vaccine offers a broad, long-lasting immune response against a range of variants," Erck said. The new variants are known to be more transmissible and are thought to have immune evasion properties, but so far, there is no sign that they cause more severe disease. Maryland-based Novavax is hoping to gain a foothold within the roughly 27 million U.S. adults who are yet to be vaccinated, particularly those who do not want to receive a vaccine like the Pfizer (PFE.N)/BioNTech (22UAy.DE) or Moderna Inc (MRNA.O) shots based on groundbreaking messenger RNA (mRNA) technology. Novavax is the Newest COVID-19 Vaccine. But the Biden administration earlier this week purchased 3.2 million doses of the vaccine in anticipation of the shot soon receiving a green light from the agency. The vaccines were rigorously tested to assess their safety and. Meanwhile, the CDC said the level of the dominant BA.2.12.1 subvariant, first seen in New York, continued to rise and is at 62.2% of sequenced samples, up a bit from 59.2% last week. For those following Novavax, the company spent decades trying to get various vaccines approved by the FDA, and the very undoing of the company could be the approval of the covid vaccine. "Todays authorization offers adults in the United States who have not yet received a Covid-19 vaccine another option that meets the FDAs rigorous standards for safety, effectiveness and manufacturing quality needed to support emergency use authorization," FDA Commissioner Dr. Robert Califf said in a statement. U kunt uw keuzes te allen tijde wijzigen door te klikken op de links 'Privacydashboard' op onze sites en in onze apps. Hannah Beier/Bloomberg via Getty Images, FILE. COVID-19 vaccines remain the best preventive measure against severe disease caused by COVID-19 and I encourage anyone who is eligible for, but has not yet received a COVID-19 vaccine, to consider doing so.. A CDC panel may consider the Novavax shots late next week. In June, the FDAs external advisory committee of experts voted 21-to-0 with one abstention to recommend the agency authorize the Novavax vaccine. During today's meeting, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) was asked to weigh the benefits and risks in people ages 18 and older. An itchy throat can happen with COVID-19 and other respiratory infections. The shot has already been cleared for use in more than 40 countries, as well as the European Union, but manufacturing problems have hampered the company's efforts to be authorized in the U.S. Novavaxs COVID-19 vaccine has cleared the Food and Drug Administrations (FDA) vaccine advisory committee, but still has more waiting to do as the agency reviews changes to the companys manufacturing process. The stock soared to amazing heights on exuberance around the approved covid vaccine, but now the gig is up. Berkeley Lovelace Jr. is a health and medical reporter for NBC News. The Fact Sheet for Recipients and Caregivers informs that in most people who have had myocarditis or pericarditis after receiving the vaccine, symptoms began within 10 days following vaccination and that vaccine recipients should seek medical attention right away if they experience any of the following symptoms after vaccination: chest pain, shortness of breath, feelings of having a fast-beating, fluttering or pounding heart. At today's meeting, Filip Dubovsky, MD, MPH, Novavax's senior vice president and chief executive officer, said the company expects in the coming months to seek clearances for expanded age indications and use as a booster dose. Nearly fifteen months after the first coronavirus vaccine gained emergency use authorization by the US FDA (and 555 million jabs in American arms later), Maryland-based Novavax is one step closer . However, the studies need to be done to actually determine whether that is a good idea, said Cohen. In addition, a study published earlier this year in the New England Journal of Medicine found that the vaccine was 90.4 percent effective against laboratory-confirmed, symptomatic infection, and 100 percent effective against moderate and severe disease. As a condition of authorization, the company will conduct studies to further assess its safety, including studies to further assess the risks of myocarditis and pericarditis. "We hopefully expect to have product in the U.S. in our warehouse by the end of June," he said in an interview, adding that the company plans to ship millions of doses made by its partner, the Serum Institute of India, soon after authorization. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. Sign up now for a risk-free, 2-week trial to start finding the next stock with the potential to generate excessive returns inthe next few years without taking onthe out sized risk of high flying stocks.. While this vaccine has been slow to get out of the gate, supporters say this more traditional vaccine still has a role to play in the countrys ongoing fight against coronavirus. The Biden administration secured 3.2 million doses of Novavax's COVID-19 vaccine. Novavaxs vaccine uses an older technology than other Covid-19 vaccines: a recombinant protein made with moth cells. Americans have been ditching Covid-19 precautions such as face mask wearing as if they were furry boots, shutter shades, or neon activewear. New COVID-19 boosters could be authorized by the FDA before full data from human trials are in because of past data on similar vaccines. At the meeting, the FDA asked the company to add myocarditis as a risk factor on its product insert. Federal government signs deal to make Novavax COVID vaccine at Montreal facility . The spike protein in this vaccine is produced in insect cells; the Matrix M-adjuvant contains saponin extracts from the bark of the Soapbark tree that is native to Chile. Novavax nears FDA advisory meeting date . In short, Novavax's Covid-19 vaccine could receive another shot in the arm from this submission if approved. I am not receiving compensation for it (other than from Seeking Alpha). Given so many Americans have yet to receive their boosters despite the clear indication of their impact on reducing risk of severe complication from COVID-19, that improvement in vaccine uptake may be somewhat limited," said John Brownstein, Ph.D., an epidemiologist at Boston Children's Hospital and an ABC News contributor. Management doesn't expect vaccine sales during Q1, with an anticipation for a seasonal shift starting in Q2, leading to substantial cash burn in the 1H of the year before the company even knows the level of vaccine sales for the rest of the year. Is this happening to you frequently? Learn more. June 7 (Reuters) - Advisers to the U.S. Food and Drug Administration on Tuesday voted overwhelmingly to recommend that the agency authorize Novavax Inc's (NVAX.O) COVID-19 vaccine for use in adults, which the drugmaker hopes can become the shot of choice among some American vaccine skeptics. "It's important for people to have a choice as they evaluate how to stay protected against COVID-19, and boosters are an invaluable tool to build upon immunity obtained from previous vaccinations," Stanley C. Erck, President and Chief Executive Officer of Novavax, said in a statement on Monday.

Man Killed In Farm Accident Today, Signs Your Baby Daddy Still Loves You, Kathryn Quadracci Flores, Schenectady Drug Bust 2021, Chris Staples Dunker Wife, Articles N